Brief description not available

Researchers at the University of California, Davis, have created a technology that uses engineered polynucleotides to deliver both an antigen and an enzyme that breaks down amino acids. This approach is designed to boost long-lasting memory T-cell responses, providing stronger protection against infectious diseases and cancer.

An innovative brachytherapy applicator designed to deliver precise radiation to challenging gynecologic cancer sites while sparing healthy tissue.

The invention describes a platform technology that increases MHC presentation of oncogene derived peptide neoantigens that do not normally occur in the cell.  The platform has already been used to identify a method of increasing KRAS G12 D/V derived peptide presentation on MHC- I.

The ability to precisely control gene expression is fundamental to advancing biotechnology and medicine, yet designing functional synthetic promoters for eukaryotic cells remains a complex challenge. UC Berkeley researchers have developed a high-throughput platform for the generation and selection of synthetic transcriptional promoters. This technology utilizes expansive libraries of recombinant expression vectors to identify promoter sequences with optimized performance characteristics. By linking promoter sequence to measurable expression outputs, the method allows for the rapid discovery of highly functional, custom-tuned regulatory elements that are compatible with a variety of eukaryotic host systems.

As global plastic pollution intensifies, the accumulation of microplastics from partial degradation remains a critical environmental threat. To address this, researchers at UC Berkeley have developed a system for the programmable and complete depolymerization of polyesters. By incorporating a nanoscopic dispersion of enzymes directly into the plastic matrix, the technology exploits specific enzyme active sites and enzyme-protectant interactions to ensure processive degradation. This method ensures that the polymer is broken down entirely into its constituent monomers, preventing the formation of persistent microplastics that typically result from traditional degradation processes.

Traditional covalent semiconductor systems, while effective, require energy-intensive and costly synthetic methods for device fabrication. To address these processing challenges, researchers at UC Berkeley have developed a stable, ligand-free zero-dimensional (0D) perovskite semiconductor ink. This ink is composed of vacancy-ordered double perovskite powders (A_2BX_6) dissolved in polar aprotic solvents like dimethyl sulfoxide (DMSO) or N,N-dimethylformamide (DMF). The process stabilizes isolated [BX_6]^{2-} octahedral anions and free A+ cations in solution without the need for organic ligands. These multi-functional inks remain stable for over a year and can be easily patterned onto various substrates—including glass and silicon—where they rapidly recrystallize into the A_2BX_6 phase upon drying.

This drug discovery platform focuses on identifying and developing covalent molecular glue stabilizers specifically designed to target 14-3-3 proteins. Researchers at UC Berkeley have engineered this system to discover small molecules that create a permanent, covalent bond between 14-3-3 adapter proteins and various disease-relevant targets. By stabilizing these protein-protein interactions (PPIs), the platform enables the sequestration and functional inhibition of proteins that are typically considered "undruggable" due to a lack of traditional binding pockets. This approach exploits the extensive regulatory network of 14-3-3 proteins, which interact with hundreds of signaling partners, to provide a modular strategy for therapeutic intervention across a wide range of human diseases.